Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Decitabine improves patient outcomes in myelodysplastic syndromes

Decitabine, a new drug undergoing Phase III efficacy trials, provides palliative therapy for patients with the bone marrow disease called Myelodysplastic Syndrome (MDS), according to a new study.

14 Mar 2006

New way to study proteins in live cells

For the first time, Johns Hopkins researchers were able to easily jumpstart the activity of a well-known cancer protein in live cells with a small molecule, a strategy that pinpointed key players in the cancer process and can be used to determine new therapeutic targets.

9 Mar 2006

Genzyme launches test to monitor Gleevec resistance

Genzyme Corporation has announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec (imatinib mesylate).

13 Feb 2006

Gene mapping project promises new targeted cancer therapies

Government researchers in the United States have this week launched a pilot project to find all the little genetic changes that cause cancer in the hope it will lead to a whole new world of targeted cancer therapy.

14 Dec 2005

AMN107 drug shows promise in leukemia resistance to Gleevec

The targeted agent AMN107 can produce dramatic benefits in patients with some forms of leukemia that are resistant to Gleevec, the standard therapy for these cancers, say researchers at The University of Texas M. D. Anderson Cancer Center.

13 Dec 2005

Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease

Scientists at the Johns Hopkins Kimmel Cancer Center have found that a gene pathway linked to a deadly form of leukemia may provide a new way to treat autoimmune diseases, including multiple sclerosis.

2 Dec 2005

Acute-leukemia sign may signal need for different therapy

A type of chromosome change that was thought to predict a good response to treatment in patients with acute myeloid leukemia (AML) might actually signal the need for a different therapy to achieve the best outcome.

19 Sep 2005

Blocking Hutchinson-Gilford progeria syndrome (HGPS) with anticancer drugs

A class of anticancer drugs currently being evaluated in phase 3 clinical trials may also be an effective treatment for Hutchinson-Gilford progeria syndrome (HGPS), a fatal genetic disorder that causes premature aging.

29 Aug 2005

Drugs known as farnesyltransferase inhibitors (FTIs) may hold promise for premature aging disorder

In a surprising development, a research team led by the National Human Genome Research Institute (NHGRI), has found that a class of experimental anti-cancer drugs also shows promise in laboratory studies for treating a fatal genetic disorder that causes premature aging.

29 Aug 2005

Discovery of new gene FANCM sheds light on repair of damaged DNA

National Institute on Aging (NIA) researchers have discovered a new gene, FANCM, which sheds light on an important pathway involved in the repair of damaged DNA.

22 Aug 2005

Data directly support a pathogenetic model of acute leukemia

Acute myeloid leukemia (AML) is frequently caused by genetic alterations that affect transcription factors, such as AML1-ETO and mutations affecting genes involved in signal transduction pathways, such as FLT3.

15 Jul 2005

Researchers develop method that can help doctors choose the best combination of drugs for fighting cancer

The method is based on a mathematical model that determines when a cancer becomes drug-resistant during therapy. It does this by estimating the probability of finding drug-resistant mutant cells at different stages of cancer progression and examining the fate of individual mutant colonies during therapy.

21 Jun 2005

Long-term outcomes studied for stem cell transplant recipients

Improved techniques and supportive care have resulted in a growing number of long-term survivors of stem cell transplants, though little is known about the impact transplants have on patients’ lives long after treatment.

23 May 2005

Giving children access to drug clinical trials is crucial, clofarabine approval shows

The accelerated approval of the drug clofarabine to treat relapsed or refractory pediatric acute lymphoblastic leukemia (ALL) demonstrates the importance of offering children rapid access to new treatments through clinical trials, according to investigators at St. Jude Children's Research Hospital. Refractory or relapsed ALL is a disease that resists treatment.

2 May 2005

Increasing benefit seen in novel drug AMN107, that treats Gleevec resistance

An investigational drug is producing powerful responses in patients resistant to Gleevec, the targeted therapy that helps most people diagnosed with chronic myeloid leukemia (CML), an international research team headed by investigators at The University of Texas M. D. Anderson Cancer Center is reporting.

23 Apr 2005

Enzyme that helps trigger the development of leukemia

Scientists at the University of North Carolina at Chapel Hill have identified an enzyme that helps trigger the development of leukemia, a cancer of blood cells.

21 Apr 2005

New gene linked to familial cancer

Scientists have identified a new gene that appears to be linked to a small but significant percentage of familial cancer cases – as well as seemingly randomly occurring malignancies.

20 Apr 2005

Feverfew or Bachelor's Button, kills human leukemia stem cells like no other single therapy

A daisy-like plant known as Feverfew or Bachelor's Button, a traditional remedy for reducing fevers and a treatment for nervousness, hysteria and low spirits, is the source of an agent that kills human leukemia stem cells like no other single therapy

23 Feb 2005

New compound AMN107 may help treat some imatinib resistant cancer cases

As scientists uncover the precise molecular mechanisms that underlie effective cancer treatments, they gain invaluable insight into why predominantly successful treatments fail for some patients.

14 Feb 2005

Compound, derived from a rare South American plant, stops the growth of human breast cancer cells

They started with a bare room and an idea. Now, after five years of painstaking, sophisticated tests, scientists at the University of Virginia Health System have discovered that a compound, derived from a rare South American plant, stops the growth of human breast cancer cells in laboratory cultures.

1 Feb 2005